Inventor · disambiguated record
Jeffrey A. Bluestone
Also filed as: BLUESTONE JEFFREY · BLUESTONE JEFFREY A
17 granted patents·24 pending applications·585 citations·filing 1993–2024
93Inventor score
Top patents by PatentIndex Score
41 records- 0196US5885573AMethods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodiesARCH DEV CORP·Filed 1993·Granted Mar 23, 1999·400 cites·3 claims
- 0293US6491916B1Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodiesTOLERANCE THERAPEUTICS INC·Filed 1994·Granted Dec 10, 2002·152 cites·5 claims
- 0390US10138298B2Anti-IL-2 antibodies and compositions and uses thereofPFIZER·Filed 2016·Granted Nov 27, 2018·14 cites·24 claims
- 0484US9977021B2CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ tregsUNIV CALIFORNIA·Filed 2015·Granted May 22, 2018·2 cites·10 claims
- 0583US7722862B2Regulatory T cells suppress autoimmunityUNIV CALIFORNIA·Filed 2006·Granted May 25, 2010·3 cites·9 claims
- 0682US11435349B2CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ TregsUNIV CALIFORNIA·Filed 2018·Granted Sep 6, 2022·1 cites·17 claims
- 0781US11459385B2Anti-IL-2 antibodies and compositions and uses thereofPFIZER·Filed 2020·Granted Oct 4, 2022·1 cites·15 claims
- 0881US9012134B2CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ TregsBLUESTONE JEFFREY A·Filed 2007·Granted Apr 21, 2015·4 cites·11 claims
- 0980US12436150B2CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ TregsUNIV CALIFORNIA·Filed 2022·Granted Oct 7, 2025·0 cites·17 claims
- 1079US12502410B2Preservation of pancreatic islet grafts in the extrahepatic spaceUNIV CALIFORNIA·Filed 2024·Granted Dec 23, 2025·0 cites·30 claims
- 1178US10738113B2Anti-IL-2 antibodies and compositions and uses thereofPFIZER·Filed 2018·Granted Aug 11, 2020·2 cites·6 claims
- 1276US11951136B2Preservation of pancreatic islet grafts in the extrahepatic spaceUNIV CALIFORNIA·Filed 2018·Granted Apr 9, 2024·1 cites·24 claims
- 1376US2025163125A1Lfa3 variants and compositions and uses thereofPFIZER·Filed 2024·Application pending·0 cites
- 1475US9801911B2Expansion of alloantigen-reactive regulatory T cellsUNIV CALIFORNIA·Filed 2013·Granted Oct 31, 2017·2 cites·9 claims
- 1574US9211328B2Modulation of NKG2D for prolonging survival of a hematopoietic graftUNIV CALIFORNIA·Filed 2013·Granted Dec 15, 2015·2 cites·17 claims
- 1665US12103958B2Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditionsPFIZER·Filed 2020·Granted Oct 1, 2024·0 cites·16 claims
- 1762US10227290B2Glycosphingolipids for use in modulating immune responsesUNIV CALIFORNIA·Filed 2013·Granted Mar 12, 2019·1 cites·12 claims
- 1859US2003108548A1Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodiesFiled 2002·Application pending·0 cites
- 1957US2024301403A1Method for making car-t librariesUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 2053US2023312673A1Chimeric receptors with diverse co-regulatory sequencesUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 2153US2018036345A1Expansion of alloantigen-reactive regulatory t cellsUNIV CALIFORNIA·Filed 2017·Application pending·0 cites
- 2253US2023340068A1Chimeric antigen receptor (car) with cd28 transmembrane domainUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 2353US2006292142A1Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodiesBLUESTONE JEFFREY A·Filed 2006·Application pending·0 cites
- 2452US2021147841A1Compositions and methods for modifying regulatory t cellsUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 2552US2021340496A1Compositions and methods for modifying regulatory t cellsUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 2652US2007190052A1Regulatory CD8cells induced with anti-CD3 antibodyUNIV COLUMBIA·Filed 2006·Application pending·0 cites
- 2752US2005186207A1Regulatory T cells suppress autoimmunityUNIV CALIFORNIA·Filed 2005·Application pending·0 cites
- 2852US2023381228A1Anti-dpp6 chimeric antigen receptor bearing regulatory t cellsUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 2950US2012064070A1Modulation of nkg2dLANIER LEWIS L·Filed 2011·Application pending·0 cites
- 3050US2006002933A1Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodiesBLUESTONE JEFFREY A·Filed 2005·Application pending·0 cites
- 3150US2010210596A1Use of aminopyrimidine compounds in the treatment of immune disordersBLUESTONE JEFFREY A·Filed 2007·Application pending·0 cites
- 3247US2002165149A1Mutated class II major histocompatibility proteinsFiled 2001·Application pending·0 cites
- 3346US2008260727A1Modulation of Nkg2dUNIV CALIFORNIA·Filed 2005·Application pending·0 cites
- 3446US2010310588A1Regulatory t cells suppress autoimmunityUNIV CALIFORNIA·Filed 2010·Application pending·0 cites
- 3546US2022281943A1Car-t cells specific for modified proteins in extracellular spacesUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 3645US12421302B2CAR-t cells and autoimmune diseasesUNIV CALIFORNIA·Filed 2019·Granted Sep 23, 2025·0 cites·20 claims
- 3744US2021017248A1Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cellsUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 3842US2003086932A1Surface-bound antigen binding portions of antibodies that bind to CTLA-4 and CD28 and uses thereforFiled 2001·Application pending·0 cites
- 3941US2016311906A1Modulation of nkg2dUNIV CALIFORNIA·Filed 2016·Application pending·0 cites
- 4040US2019388469A1Protein delivery in primary hematopoietic cellsUNIV CALIFORNIA·Filed 2016·Application pending·0 cites
- 4139US2007190045A1Anti-CD3 and antigen-specific immunotherapy to treat autoimmunityHEROLD KEVAN·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeffrey A. Bluestone files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →